A5049678335- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Immune Cell Function and Interaction
- Cell Adhesion Molecules Research
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- MicroRNA in disease regulation
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal Cancer Treatments and Studies
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
- Immunotherapy and Immune Responses
- Cancer therapeutics and mechanisms
- Pancreatic and Hepatic Oncology Research
- Esophageal Cancer Research and Treatment
- Cancer Genomics and Diagnostics
- Glycosylation and Glycoproteins Research
- Cytokine Signaling Pathways and Interactions
- Immune cells in cancer
- Circular RNAs in diseases
- Synthesis and biological activity
- HER2/EGFR in Cancer Research
- Cancer Mechanisms and Therapy
- Cancer Research and Treatments
Jiangsu Province Hospital
2014-2025
Nanjing Medical University
2015-2025
Huzhou University
2025
Jiangsu Provincial Hospital of Traditional Chinese Medicine
2020-2024
Suzhou Municipal Hospital
2023
Qilu Hospital of Shandong University
2015
Affiliated Hospital of Jiangsu University
2014
Yangzhou University
2014
Jiangsu Cancer Hospital
2012
Chinese Academy of Medical Sciences & Peking Union Medical College
2012
Platinum-based chemotherapy is the standard first-line treatment for advanced esophageal squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial.gov: NCT03829969), 514 patients with treatment-naïve ESCC were randomized (1:1) to receive toripalimab or placebo in combination paclitaxel plus cisplatin (TP) every weeks up 6 cycles, followed by maintenance. At prespecified final analysis of progression-free survival (PFS), a significant improvement PFS observed arm over (hazard ratio...
Abstract Background Current treatment options for human epidermal growth factor receptor 2 (HER2)‐overexpressing gastric cancer at third‐line have shown limited clinical benefit. Further, there is no specific HER2 immunohistochemistry (IHC) 2+ and fluorescence in‐situ hybridization‐negative patients. Here, we report the efficacy safety of a novel anti‐HER2 antibody RC48 patients with HER2‐overexpressing, advanced or gastroesophageal junction cancer. Methods Patients HER2‐overexpressing (IHC...
Importance Gastric and gastroesophageal junction cancers are diagnosed in more than 1 million people worldwide annually, few effective treatments available. Sintilimab, a recombinant human IgG4 monoclonal antibody that binds to programmed cell death (PD-1), combination with chemotherapy, has demonstrated promising efficacy. Objective To compare overall survival of patients unresectable locally advanced or metastatic gastric who were treated sintilimab chemotherapy vs placebo chemotherapy....
The dysregulation of microRNAs (miRNAs) has been demonstrated to contribute drug resistance cancer cells, and sustained nuclear factor (NF)κB activation is also pivotal in tumor chemotherapy. In the present study, an essential role for miRNA (miR)-20a was identified regulation gastric (GC) chemoresistance. expression level miR‑20a assayed by reverse transcription‑quantitative polymerase chain reaction. Additionally, 3-(4,5-dimethylthiazol-2‑yl)-2,5-diphenyltetrazolium bromide used detect...
To detect effects of plumbagin on proliferation and apoptosis in non-small cell lung cancer lines, investigate the underlying mechanisms.Human lines A549, H292 H460 were treated with various concentrations plumbagin. Cell rates was determined using both counting kit-8 (CCK-8) clonogenic assays. Apoptosis detected by annexin V/propidium iodide double-labeled flow cytometry TUNEL assay. The levels reactive oxygen species (ROS) cytometry. Activity NF-κB examined electrophoretic mobility shift...
Genetic variation may influence chemotherapy response and overall survival in cancer patients.We conducted a genome-wide scan 535 advanced-stage non-small cell lung (NSCLC) patients from two independent cohorts (307 Nanjing 228 Beijing). A replication was carried out on an cohort of 340 Southeastern China followed by second validation 409 the Massachusetts General Hospital (Boston, MA).Consistent associations with NSCLC were identified for five single-nucleotide polymorphisms (SNP) Chinese...
We investigated the possible role of miR-143 in development cisplatin resistance human gastric cancer cell line. was detected by quantitative real-time PCR. Cisplatin changes cells tested via MTT assay. Target genes were verified dual-luciferase activity Immunohistochemistry, immunofluorescence staining, Western blot, proliferation, and clonogenic apoptosis assay used to elucidate mechanism formation. downregulated tissues lines. It also cisplatin-resistant line SGC7901/cisplatin (DDP),...
Abstract Background Chronic inflammation is a well-known risk factor for the development of gastric cancer (GC). Nevertheless, molecular mechanisms underlying inflammation-related GC progression are incompletely defined. Methods Bioinformatic analysis was performed based on data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), expression miR-26b-5p in cells tissues validated by quantitative real-time PCR (qRT-PCR). Cell proliferation examined through Counting Kit-8...
Background: Amphiregulin (AREG) and epiregulin (EREG) have been found to play pivotal roles in several malignancies. However, the correlation between their expression clinicopathological factors colorectal carcinoma (CRC) is yet be further investigated. To clarify clinical significance of AREG EREG CRC, we detected serum tissue levels EREG. Patients Methods: We by ELISA, immunohistochemical test 73 patients with CRC. The each independent characteristic was examined. Results: There...
Over the last decades, combined chemotherapies that inhibit different signalling pathways together have been demonstrated to be more effective treat non-small-cell lung cancer (NSCLC). The epidermal growth factor receptor (EGFR) and vascular endothelium (VEGF) are two key targets. Polymorphisms in EGFR VEGF genes identified associated with therapy–response survival. In this study, we hypothesized single-nucleotide polymorphisms (SNPs) of NSCLC patients' survival Chinese. Therefore, screened...
4511 Background: Patients (pts) with advanced esophageal squamous cell carcinoma (ESCC) refractory to first-line chemotherapy have limited treatment options. The study aims evaluate the efficacy and safety of sintilimab, a PD-1 inhibitor, versus in these pts, explore predictive value PD-L1 neutrophil-to-lymphocyte ratio (NLR) on sintilimab. Methods: open-label, multi-center phase 2 trial (NCT03116152) enrolled ESCC pts chemotherapy, randomly assigned (1:1) them receive sintilimab (200mg,...